Navigation Links
Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline (KW-6002)
Date:2/27/2008

TOKYO, Feb. 27 /PRNewswire/ -- Kyowa Hakko Kogyo Co., Ltd. (President: Dr. Yuzuru Matsuda) announced that Kyowa Pharmaceutical, Inc. (New Jersey, United States), its wholly owned U.S. subsidiary, received on February 25, 2008 (local time) a Not approvable letter from the U.S. Food and Drug Administration (FDA) for istradefylline (KW-6002), its investigational drug for the treatment of Parkinson's disease.

In the not approvable letter FDA expressed concern if the efficacy findings support clinical utility of istradefylline (KW-6002). FDA requested an overall summary of nonclinical mineralization findings. Additionally, FDA asked for clinical pharmacology follow-up information as a Phase 4 commitment.

After closely examining the FDA's response, Kyowa Hakko will work closely with FDA and conduct a comprehensive discussion to determine a path forward for istradefylline (KW-6002).

Istradefylline (KW-6002) has a novel mechanism of action that antagonizes the adenosine A2A receptor. It has been under FDA review as adjunctive therapy to levodopa/carbidopa for the treatment of idiopathic Parkinson's disease to improve motor function in patients who experience motor response complications.

Kyowa Hakko is a biotechnology-based company focused on two businesses: pharmaceutical operations engaged in the research and development, manufacturing, and marketing of prescription drugs; and bio-chemical operations that handle a variety of products such as amino acids, nucleic acids, and nutritional supplements/healthcare products. Its pharmaceutical business places emphasis on research and development in the fields of oncology, allergy, and the central nervous system. In Japan, Kyowa Hakko is marketing medications for a wide range of diseases, including allergy, hypertension, angina pectoris, and cancer. With the aim of penetrating the global market, Kyowa Hakko has overseas development bases in the U.S. (Kyowa Pharmaceutical, Inc. and BioWa, Inc.) and in the U.K. (Kyowa Hakko U.K. Ltd.). In the U.S., U.K., and China, they are pushing ahead with the clinical development of new drug candidates as well as the therapeutic antibody business based on Kyowa Hakko's proprietary technology (POTELLIGENT) that enhances the activity of antibodies.

Last autumn, Kyowa Hakko announced that the Kyowa Hakko group and the Kirin group entered into an agreement to form a strategic business/capital alliance. Through this tie-up, the two groups will endeavor to build a global leader in the research and development-driven life sciences business based in Japan, which is centered on pharmaceutical operations with strengths in biotechnology. The new company "Kyowa Hakko Kirin Co., Ltd." will start operating on October 1, 2008.

Contact:

TETSURO KUGA, Public Relations

Kyowa Hakko Kogyo Co., Ltd.

1-6-1, Ohtemachi, Chiyoda-ku, Tokyo, Japan 100-8185

Tel: +81-3-3282-1903

Fax: +81-3-3282-0990

e-Mail: info@kyowa.co.jp

URL: http://www.kyowa.co.jp/eng/index.htm


'/>"/>
SOURCE Kyowa Hakko Kogyo Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2019)... ... January 07, 2019 , ... Kainos ... its Parkinson's Disease drug candidate, code-named "KM-819." KM-819 is an orally active ... took place in South Korea. , This Phase 1 randomized, double-blind, placebo-controlled ...
(Date:1/4/2019)... ... January 03, 2019 , ... Calidi Biotherapeutics, Inc., ... today announced the founding of a scientific and medical advisory board (SMAB). The ... leaders in the Immuno-Oncology field. The founding members of Calidi Biotherapeutics SMAB include ...
(Date:12/18/2018)... ... 17, 2018 , ... ABCT , the Accelerator for ... to participate in the annual program. Twelve ventures will participate in the 6.5-month-long ... network. All startups receive an entrepreneur coach, access to active business professionals and ...
(Date:12/13/2018)... ... December 11, 2018 , ... ... and nurses can use to quickly detect Clostridium difficile (C. diff), a dangerous ... of a handheld device that can be used onsite in doctor’s offices and ...
Breaking Biology Technology:
(Date:12/13/2018)... ... 13, 2018 , ... Biocompare, the leading online information resource ... Need to Know about Antibody Manufacturing” . This educational resource is the third ... this film is to educate scientists about antibody production, validation, and responsible sourcing. ...
(Date:12/6/2018)... ... , ... Stewart has been on the business side of ... During his recent five-year tenure with InSphero he was the US General Manger ... in Brunswick, Maine. Through these experiences, Stewart has a deep understanding of the ...
(Date:12/5/2018)... ... December 03, 2018 , ... uBiome, the leader in microbial ... the Division of Gastroenterology and Hepatology at UC San Diego and staff gastroenterologist ... the board of leading scientists and doctors from around the world, Dr. Zarrinpar ...
Breaking Biology News(10 mins):